Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 8, 2016

Sartorius Stedim Biotech Acquires kSep Systems

The company acquired kSep Holdings, a single-use bioprocessing solutions company.

Sartorius Stedim Biotech (SSB) announced on July 6, 2016 that it will acquire kSep Holdings, a single-use bioprocessing solutions company based in Morrisville, North Carolina. The transaction valued kSep at approximately $28 million and will be closed by the end of July 2016. kSep markets single-use, fully automated centrifugation systems used for manufacturing biopharmaceuticals, such as vaccines, cell-based therapeutics, and monoclonal antibodies. kSep Systems is a spinoff from KBI Biopharma and was established in 2011.


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.